The Top 5 Biosimilar Articles for the Week of August 28

Here are the top 5 biosimilar articles for the week of August 28, 2023.

Hi, I’m Justina Petrullo for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of August 28th, 2023.

Number 5: Stelara (ustekinumab) and Enbrel (etanercept), 2 originator medications that will face biosimilar competition within the next decade, were among the 10 preliminary drugs chosen for Medicare price negotiation under the Inflation Reduction Act (IRA).

Number 4: A meta-analysis and systematic review of data on over 10,000 patients with rheumatoid arthritis (RA) found that etanercept, adalimumab, and infliximab biosimilars were clinically equivalent to their reference products.

Number 3: Dan Danielson, RPh, MS, senior director, market access solutions, at PrecisionValue, a market access marketing firm, explained the remaining issues at play slowing down biosimilar uptake in the United States.

Number 2: Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, published her opinions on the future of biosimilars in the United States, foreshadowing immense growth and a transformation of the US health care industry thanks to biosimilars.

Number 1: The FDA approved its first biosimilar indicated for multiple sclerosis (MS), Sandoz’ Tyruko (natalizumab-sztn), a biosimilar referencing Tysabi (natalizumab).

To read all of these articles and more, visit centerforbiosimilars.com.